Multiple Myeloma, Plasma Cell Leukemia Clinical Trial
| NCT number | NCT01248923 |
| Other study ID # | ARRAY-520-111 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 1 |
| First received | |
| Last updated | |
| Start date | December 2010 |
| Verified date | September 2020 |
| Source | Array BioPharma |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma
(MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and
bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF)
support.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF
support or (2) bortezomib and dexamethasone with G-CSF support, in order to achieve the
highest dose of study drug possible that will not cause unacceptable side effects.
Approximately 45 patients from the US will be enrolled in Part 1 (Active, not recruiting).
In the second part of this study, patients will receive the best dose(s) and schedule(s) of
study drug, in combination with bortezomib ± dexamethasone + G-CSF, determined from the first
part of the study and will be followed to see what side effects the combination causes and
what effectiveness the combination has, if any, in treating the cancer. Approximately 42
patients from the US will be enrolled in Part 2 (Active, not recruiting).
| Status | Completed |
| Enrollment | 55 |
| Est. completion date | |
| Est. primary completion date | March 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Key Inclusion Criteria (Part 1 and Part 2): - Confirmed relapsed or refractory MM (measurable disease) or PCL. - Prior treatment regimens for Part 1: Patients should have received at least 2 prior treatment regimens. Prior treatment must have included at least one full cycle of a proteasome inhibitor (e.g., bortezomib or carfilzomib) and at least one full cycle of an IMiD (e.g., thalidomide, lenalidomide or pomalidomide). - Prior treatment regimens for Part 2: Patients should have received 1 to 3 prior treatment regimens. Prior treatment could have included bortezomib only if the disease was not refractory to treatment with bortezomib (refractory defined as documented progression on therapy or within 60 days of completing treatment with bortezomib). - The disease should have progressed per IMWG criteria during or after the last prior treatment regimen. - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. - Adequate hematology laboratory values without transfusion support and without hematological growth factor support within 2 weeks of screening. - Adequate liver and renal function. - Additional criteria exist. Key Exclusion Criteria (Part 1 and Part 2): - Primary amyloidosis. - Peripheral neuropathy = Grade 2 or neuropathy with pain, regardless of grade. - Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low grade prostate cancer may enroll irrespective of the time of diagnosis). - Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug. - Treatment with an investigational medicinal product or device within 28 days prior to first dose of study drug. - Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study drug. - Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal covered = 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy). - Major surgery within 14 days and minor surgery within 7 days prior to first dose of study drug. - Corticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to first dose of study drug. - Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C. - Additional criteria exist. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
| United States | Emory University, Winship Cancer Institute | Atlanta | Georgia |
| United States | Charleston Hematology Oncology Associates | Charleston | South Carolina |
| United States | Baylor Charles A. Sammons Cancer Center at Dallas | Dallas | Texas |
| United States | Karmanos Cancer Institute | Detroit | Michigan |
| United States | City of Hope | Duarte | California |
| United States | The Jones Clinic | Germantown | Tennessee |
| United States | Clearview Cancer Institute | Huntsville | Alabama |
| United States | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee |
| United States | Mount Sinai Medical Center | New York | New York |
| United States | NYU Cancer Center | New York | New York |
| United States | Associates in Oncology/Hematology | Rockville | Maryland |
| United States | Arizona Clinical Research Center, Inc. | Tucson | Arizona |
| Lead Sponsor | Collaborator |
|---|---|
| Array Biopharma, now a wholly owned subsidiary of Pfizer |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms. | Part 1 | ||
| Primary | Establish the maximum tolerated dose (MTD) of the study drug in combination with bortezomib ± dexamethasone + G-CSF. | Part 1 | ||
| Primary | Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of best overall response | Part 2 | ||
| Secondary | Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of duration of response, time to progression, treatment-free interval and time to next treatment. | Part 1 and Part 2 | ||
| Secondary | Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms. | Part 2 | ||
| Secondary | Assess the pharmacokinetic (PK) drug interactions between ARRY-520 and bortezomib in terms of plasma concentration-time profiles. | Part 2 |